Abstract
BackgroundImmune checkpoint inhibitors (ICIs) have had a profound impact on the treatment of many tumors; however, their effectiveness against triple-negative breast cancers (TNBCs) has been limited. One factor limiting responsiveness...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have